Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s): CRDL

Healthcare

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

TSX:CRDL - Post by User

Cardiol Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Youhillmanon May 03, 2021 8:57pm

181 Views

Post# 33120861

May’s Corporate Presentation

Attached below is the link to this month's Corporate Presentation.

From my standpoint it looks to me like there's more detailed information regarding Phase One for AM.

Also if you look at slide 29 - the 12 month milestones - it appears to me that they are ranked in terms of importance to CRDL.

Phase 2/3 for Covid has started, we should get the results in the 3rd quarter of 2021 with hopefully FDA approval.

I'm long on CRDL!

https://www.cardiolrx.com/wp-content/uploads/2021/05/Cardiol-Therapeutics-Corporate-Presentation-May-2021.pdf

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland